Synapse - Steven Horwitz

Results (669)

Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: Real-life experience

Journal Article

Cassanello, G.; Drill, E.; Rivas-Delgado, A.; Okwali, M.; Isgor, I.; Caron, P. C.; Epstein-Peterson, Z.; Ghione, P.; Hamlin, P. A.; Lue, J. K.; more...
Haematologica (2025)

Fulltext@MSK | Save

Polytypic B cells, monotypic/monoclonal B-cell proliferations, and neoplastic T cells diverge from TET2-/ DNMT3A-mutant clonal hematopoiesis in follicular helper T-cell lymphomas

Research Letter

Lewis, N. E.; Petrova-Drus, K.; Sardana, R.; Huet, S.; Gao, Q.; Sethi, S.; Vanderbilt, C.; Xiao, W.; Roshal, M.; Baik, J.; more...
Haematologica (2025)

Fulltext@MSK | Save

Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from the PETAL consortium

Journal Article

Han, J. X.; Koh, M. J.; Boussi, L.; Sorial, M.; McCabe, S. M.; Peng, L.; Singh, S.; Eche-Ugwu, I. J.; Gabler, J.; Fernandez Turizo, M. J.; more...
Blood Advances (2025)

Fulltext@MSK | Save

Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): A single-arm, open-label, phase 1, dose-escalation study

Journal Article

Iyer, S. P.; Sica, R. A.; Ho, P. J.; Prica, A.; Zain, J.; Foss, F. M.; Hu, B.; Beitinjaneh, A.; Weng, W. K.; Kim, Y. H.; more...
Lancet Oncology (2025)

Fulltext@MSK | Save

New treatments for adult T-cell leukemia/lymphoma

Review

Epstein-Peterson, Z. D.; Gurumurthi, A.; Horwitz, S. M.
Leukemia Research (2025)

Fulltext@MSK | Save

A phase II study of acimtamig (AFM13) in patients with CD30-positive, relapsed, or refractory peripheral T-cell lymphomas

Journal Article

Kim, W. S.; Shortt, J.; Zinzani, P. L.; Mikhailova, N.; Radeski, D.; Ribrag, V.; Domenech, E. D.; Sawas, A.; Alexis, K.; Emig, M.; more...
Clinical Cancer Research (2025)

Fulltext@MSK | Save

CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas

Journal Article

Ghione, P.; Bantilan, K. S.; Joffe, E.; Palomba, M. L.; Noy, A.; Caron, P.; Hamlin, P.; Kumar, A.; Matasar, M.; Owens, C.; more...
Blood Neoplasia (2024)

Fulltext@MSK | Save

CD38-SADA pretargeted radioimmunotherapy (PRIT) with Lutetium 177 (Lu177)-DOTA in adult patients with relapsed or refractory non-Hodgkin lymphoma: A first-in-human phase 1 trial

Meeting Abstract

Zain, J.; Wong, J.; Horwitz, S.; Pandit-Taskar, N.; Al-Janadi, A.; Mancini, B.; Khawaja, R.; Lee, C. Y.; Howansky, A.; Liles, D.; more...
Blood (2024)

Fulltext@MSK | Save

Confirmatory efficacy and safety evaluation of MB-105, a CD5.CAR T therapy: Multicenter phase 2 study in patients with relapsed/refractory T cell lymphoma (R/R TCL)